Geoffrey R. Weiss

17.1k total citations · 5 hit papers
194 papers, 13.1k citations indexed

About

Geoffrey R. Weiss is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Geoffrey R. Weiss has authored 194 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 59 papers in Molecular Biology and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Geoffrey R. Weiss's work include Cancer Treatment and Pharmacology (34 papers), Cancer therapeutics and mechanisms (31 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Geoffrey R. Weiss is often cited by papers focused on Cancer Treatment and Pharmacology (34 papers), Cancer therapeutics and mechanisms (31 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Geoffrey R. Weiss collaborates with scholars based in United States, Switzerland and France. Geoffrey R. Weiss's co-authors include Kim Margolin, Michael B. Atkins, Stephanie Green, Janice P. Dutcher, Richard I. Fisher, Mario Sznol, David R. Gandara, Michael Hawkins, David Parkinson and John Crowley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Geoffrey R. Weiss

193 papers receiving 12.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 1.5k citations Geoffrey R. Weiss, Kim Margolin et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

2001 923 citations Antoinette J. Wozniak, Geoffrey R. Weiss et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations Geoffrey R. Weiss, Theodore F. Logan et al. Journal of Clinical Oncology profile →
A Southwest Oncology Group study

1993 591 citations Geoffrey R. Weiss et al. profile →
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1992 549 citations Geoffrey R. Weiss et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Geoffrey R. Weiss United States	54	8.2k	4.6k	4.2k	2.5k	1.5k	194	13.1k
Janice P. Dutcher United States	58	6.5k 0.8×	5.8k 1.3×	6.5k 1.5×	3.4k 1.4×	3.0k 2.0×	272	14.7k
Gilbert Deray France	24	9.8k 1.2×	4.0k 0.9×	2.2k 0.5×	4.3k 1.7×	1.1k 0.7×	115	13.3k
Ross C. Donehower United States	66	10.1k 1.2×	2.7k 0.6×	5.7k 1.3×	1.1k 0.4×	1.6k 1.1×	223	16.0k
Jan B. Vermorken Belgium	59	7.0k 0.9×	3.1k 0.7×	3.4k 0.8×	1.1k 0.4×	1.7k 1.1×	371	12.8k
Bruce G. Redman United States	46	4.7k 0.6×	3.8k 0.8×	3.4k 0.8×	2.1k 0.8×	1.8k 1.2×	143	9.1k
Rosemarie Mick United States	72	6.2k 0.8×	2.6k 0.6×	3.5k 0.8×	3.2k 1.3×	2.1k 1.4×	265	14.4k
Rolf A. Stahel Switzerland	64	5.8k 0.7×	6.9k 1.5×	4.4k 1.1×	1.5k 0.6×	1.9k 1.3×	326	14.1k
Kim Margolin United States	63	11.0k 1.3×	5.6k 1.2×	6.5k 1.5×	5.5k 2.2×	2.5k 1.7×	312	17.9k
Roger B. Cohen United States	56	9.2k 1.1×	5.9k 1.3×	5.4k 1.3×	1.6k 0.6×	1.9k 1.2×	328	17.5k
Christophe Massard France	59	7.0k 0.9×	6.0k 1.3×	2.8k 0.7×	1.6k 0.6×	2.5k 1.6×	432	12.6k

Countries citing papers authored by Geoffrey R. Weiss

Since Specialization

Citations

This map shows the geographic impact of Geoffrey R. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey R. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey R. Weiss more than expected).

Fields of papers citing papers by Geoffrey R. Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey R. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey R. Weiss. The network helps show where Geoffrey R. Weiss may publish in the future.

Co-authorship network of co-authors of Geoffrey R. Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey R. Weiss. A scholar is included among the top collaborators of Geoffrey R. Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey R. Weiss. Geoffrey R. Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oliver, Ronald, Brian Hughes, & Geoffrey R. Weiss. (2018). A Study of the Self-Reported Resilience of APC Chaplains. Journal of Pastoral Care & Counseling Advancing theory and professional practice through scholarly and reflective publications. 72(2). 99–103. 14 indexed citations

Slingluff, Craig L., Gina R. Petroni, David L. Brautigan, et al.. (2013). Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research. 19(13). 3611–3620. 28 indexed citations

Kahaleh, Michel, Rajnish Mishra, Vanessa M. Shami, et al.. (2008). Unresectable Cholangiocarcinoma: Comparison of Survival in Biliary Stenting Alone Versus Stenting With Photodynamic Therapy. Clinical Gastroenterology and Hepatology. 6(3). 290–297. 111 indexed citations

Ricart, Alejandro D., Anthony W. Tolcher, Quincy S. Chu, et al.. (2006). Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies. Cancer Research. 66. 685–685. 3 indexed citations

Mita, Monica, Eric K. Rowinsky, Leonardo Forero, et al.. (2006). A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. 59(2). 165–174. 32 indexed citations

Davies, Angela M., Kari Chansky, Derick Lau, et al.. (2006). Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712. Journal of Clinical Oncology. 24(33). 5242–5246. 30 indexed citations

Osborn, Blaire L., Mili Gu, Krzysztof Grzegorzewski, et al.. (2004). Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients. Cancer Research. 64. 1099–1099. 9 indexed citations

deGraffenried, Linda A., Bysani Chandrasekar, William E. Friedrichs, et al.. (2004). NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Annals of Oncology. 15(6). 885–890. 111 indexed citations

Villalona‐Calero, Miguel A., Geoffrey R. Weiss, Howard A. Burris, et al.. (1999). Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 17(6). 1915–1915. 69 indexed citations

10.

Marshall, M. Ernest, Michael Wolf, E. David Crawford, et al.. (1995). Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate. American Journal of Clinical Oncology. 18(5). 400–402. 4 indexed citations

11.

Havlin, Kathleen A., James M. Koeller, David H. Boldt, et al.. (1995). Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.. PubMed. 6(2). 229–36. 7 indexed citations

12.

Margolin, Kim, Frederick R. Aronson, Mario Sznol, et al.. (1994). Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. Journal of Immunotherapy. 15(2). 147–153. 51 indexed citations

13.

Burris, Howard A., John G. Kuhn, Lee Smith, et al.. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology. 11(5). 950–958. 120 indexed citations

14.

Myers, Christopher D., Michael R. Cooper, C.A. Stein, et al.. (1992). Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.. Journal of Clinical Oncology. 10(6). 881–889. 200 indexed citations

15.

Havlin, Kathleen A., John G. Kuhn, John B. Craig, et al.. (1991). Phase I evaluation of 773U82 HCI, a member of a new class of DNA intercalators. Anti-Cancer Drugs. 2(4). 357–364.

16.

Arteaga, Carlos L., et al.. (1989). Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).. PubMed. 49(16). 4648–53. 52 indexed citations

17.

Weiss, Geoffrey R., Gisele Sarosy, Todd D. Shenkenberg, et al.. (1989). A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). European Journal of Cancer and Clinical Oncology. 25(12). 1867–1873. 8 indexed citations

18.

Saez, Ruben A., John B. Craig, John G. Kuhn, et al.. (1989). Phase I clinical investigation of amonafide.. Journal of Clinical Oncology. 7(9). 1351–1358. 34 indexed citations

19.

Craig, John B., John G. Kuhn, Jay Luther, et al.. (1988). Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.. PubMed. 48(16). 4706–10. 12 indexed citations

20.

Weiss, Geoffrey R., et al.. (1978). Bactericidal and opsonic activity of cirrhotic ascites and nonascitic peritoneal fluid.. PubMed. 91(5). 831–9. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact